{"name":"Neurana Pharmaceuticals, Inc.","slug":"neurana-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tolperisone Hydrochloride","genericName":"Tolperisone Hydrochloride","slug":"tolperisone-hydrochloride","indication":"Muscle spasticity associated with neurological disorders","status":"phase_3"}]}],"pipeline":[{"name":"Tolperisone Hydrochloride","genericName":"Tolperisone Hydrochloride","slug":"tolperisone-hydrochloride","phase":"phase_3","mechanism":"Tolperisone hydrochloride is a centrally acting muscle relaxant that reduces muscle tone and spasticity by modulating neural pathways in the spinal cord.","indications":["Muscle spasticity associated with neurological disorders","Post-stroke spasticity","Spinal cord injury-related spasticity"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNVQyZUFuNVQxV1VrbFZLRlllZkI5bjdfQzU5bjJGSk05M21OZW55Zk1pX29JUjAtWlBzQzhZX1VrVEJwYlN0QXBDWk8wT2o5YXI3ZHZTbDd0Slg2YXhXbmk0WjctVmlmdzRYY1lfZEJjVlZyamVKUlh0cnNMbDZwblFOdDAyWmltX3pzcDhXckZsRU85QTdIQWRpNVRzSjlzN0dWM1dGQ3lWUQ?oc=5","date":"2026-03-09","type":"trial","source":"Seeking Alpha","summary":"Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE) - Seeking Alpha","headline":"Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPMW1jb1NCSnFLRVVINXFianoxbTd6Y1lFQ2RNNHJZVzYxb2JUczRzajdPc2d0RVQ2eDlZWENZZ1VSZkZBRUlJSGdKblFNU3ctbkV1MkI0aVdETFctUTZ6TVg0UldXaHVnWGxXcVlkaWdPNnIwa0VXRWN4cVJLYWstOXloQXIyaDNQcDAwYnRNQjVvN3AxaVdBaEt4MEhhT0MzQmc?oc=5","date":"2025-08-25","type":"pipeline","source":"NYU Langone Health","summary":"Most Epilepsy Patients Wait a Year After Starting Treatment for Seizure Relief - NYU Langone Health","headline":"Most Epilepsy Patients Wait a Year After Starting Treatment for Seizure Relief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSk9fSzZOeVAydV9fXzVPdHBJZG5jUjRfN0pNT3JtMXFrZFh1RVhJekJYSzBSdlBZNVBrQWJ0SkhMaWNjMjBJa3JsTFJnSkpocGFzNWlTb09BWWR6NE5RX1pQV1NTUXVsLTJmZU1Rcl9aM05MRVBpOVhZWGRBY3VkRjMzeHBSRS1nSm00a1k1ZVFhdUZ4Rm9aYnFOTGdsek1iU0p5WDNEd090WENRM252Ny1XNlRYdFB3YXY0?oc=5","date":"2025-04-03","type":"pipeline","source":"Pharmaceutical Technology","summary":"Neurona raises $102m to advance cell therapy for drug-resistant epilepsy - Pharmaceutical Technology","headline":"Neurona raises $102m to advance cell therapy for drug-resistant epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9kXzdLWVNUbUZPWWZhZGNGYnUwSllCSW1Edk9tcVlvcV8wUVY5QlpNN2xYX18ydFNTSUVseUg5cFJUTHVUZkgtUGVyMDh2YkloU193?oc=5","date":"2025-04-03","type":"trial","source":"FirstWord Pharma","summary":"Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy - FirstWord Pharma","headline":"Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5lMGp2c01DMXM2dmdjVWNXYjRmNUV1U1VMdlNhUW1vdUhyZDdqOERKeVl4aHdZZ3ExS2dWMmJhVWdwODRxel9OR3V4WFBZRTROa0ZaNG1tV1NaYXRCTW82akY0anRMOFZXaF9wV29Lc1lCWUJo?oc=5","date":"2024-07-14","type":"pipeline","source":"The Pharma Letter","summary":"Neurona Therapeutics - The Pharma Letter","headline":"Neurona Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQcmJRZ1h3UjV2TFl0cVRVbWd3V1p1Q3pUek1pNTNENHNobndXVFQ5UnpQS1lXU3dVa3RSeC13bGkyWnFvQ0YyMkx6OEpJMExLVmREa0xyYUU3YzU4aWhOa3QydjN0dlBSUmg1aEgzNW02NkpCNjEzcVprbHhaemxKNjNBNDNLS0pmbEJLVmxaRWtVdEJ2SGdVZ1ZpR3QzaHZWT2ZXbQ?oc=5","date":"2024-02-16","type":"pipeline","source":"pharmatimes.com","summary":"Neurona secures $120m to advance lead cell therapy candidate for epilepsy - pharmatimes.com","headline":"Neurona secures $120m to advance lead cell therapy candidate for epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQ3FpSXdUNDc2Z01Gd0c1bzltd1JqNkVUc2s1LTNPV0JiNGRDNXVDVU1xMV9iaUJ4SWVkeV9TazhvY1pHR1daazJqN3RldFpnYnA0Tks4MXFYV3BreTQ0Y2sxLUFrbFRwOUZQVHBpY3BBb0ZOTTlCZzI0Z0N6SS1tU3N5VkxKT3lYRGNwd2l5TVlnZnQx?oc=5","date":"2024-02-08","type":"pipeline","source":"BioPharma Dive","summary":"Neurona raises another $120M for brain disease cell therapies - BioPharma Dive","headline":"Neurona raises another $120M for brain disease cell therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQS2VHSU42M3B1RXQ4bUJnT2xfRFdxcTFULTJYZndGMTlQT2dBaUp2R0daMzZXMHFPZU9vWDQ0a0dTME9OVmlQVkp2bTFKZ04xVng1TUNVbGY4MllHbURIcTNiV3hNZlpkR0E1U2FEZVZOaXFqbGYxN2h5RUpaOWp1MmszTFk3bW1tTXlCNnB1RVgyNncwY1Npend1ZlNrSS00QmhWcWFUZ1ppd1gzUk4tRW9LQzNpVzRxVmdpNzdObWhobnB5WE1KNmhiNGlRVkFCSEl2VHREVFd4SDBqQnBKSU5oMUVZTUZHQjNseVNmTndfUndUZUw4?oc=5","date":"2023-04-11","type":"pipeline","source":"PR Newswire","summary":"DelveInsight Evaluates a Robust Epilepsy Pipeline as 70+ Influential Pharma Players to Set Foot in the Domain - PR Newswire","headline":"DelveInsight Evaluates a Robust Epilepsy Pipeline as 70+ Influential Pharma Players to Set Foot in the Domain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPQmtxaDBrc1Y5TlMzb3paajNWZjcyV01kMldzYU5QMlpKNnZkV2x2enI5bTRIdE9rNkgwMmR6aWZCWm9GWm1pTTFHZzVhd0RCSUhwUnhINnZWY2ZGS1RyLU40VEhEWnRlT1YzUnh3RUJ2VEIwYmFXWlVOLUthYXdoUmljOTM5MzBIVEUwWXhhQkpRQ3paOVBJcGR2WFZoZw?oc=5","date":"2022-03-23","type":"pipeline","source":"BioSpace","summary":"Neurana, Aurobindo and ORIC Face Tough Decisions, Layoffs - BioSpace","headline":"Neurana, Aurobindo and ORIC Face Tough Decisions, Layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQSnQ4bU4yM1VZcU1kNHg1N2t5cUNYcFFWMG90bTFLNHpCQWt4eEh2UExEaVU2a2hqdzNTX2pfNTYtR2JsNU1ZWENiYVpYdnpISlp1MEl6Ti1hdVFQdlY0VlZiRU42R2pRNkpWd2oxWHFDSUNrc3pSX0toOEJBTFRFYzJ2LUdVWHpHS1FxNVRUZkIwSEt1UzA1MjA4RlZUMThpNVlnUmRLcUZDdEpraE5CWFE1dnpkVjR3Y21NZTVzbnNYenVfeFFSSHFaV2p4dVBaM0NPWER3LUxjN0FKNEduV0FQaEhNMVVaemZPMzNHU19Kbk1DVjlhY0prTjhGd1EzVnIxc1NOYkh4UmJlTkhlcTNubkhlUnRsc1VRMTlJa0h2RGJnTVFfejdQamxUdHU0RDM4?oc=5","date":"2022-03-21","type":"pipeline","source":"globenewswire.com","summary":"Longboard Pharmaceuticals Announces the Appointment of - globenewswire.com","headline":"Longboard Pharmaceuticals Announces the Appointment of","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}